Nirsevimab Linked to Lower Infant Hospitalization Risk Than Maternal Vaccine - Summary - MDSpire

Nirsevimab Linked to Lower Infant Hospitalization Risk Than Maternal Vaccine

  • By

  • Andrea Surnit

  • April 24, 2026

  • 3 min

Share

Objective:

To compare the risk of hospitalization for respiratory syncytial virus (RSV) in infants receiving nirsevimab versus those whose mothers were vaccinated during pregnancy.

Key Findings:
  • 44% of hospitalizations occurred in the nirsevimab group compared to 56% in the maternal vaccination group.
  • Nirsevimab was associated with a 26% lower likelihood of RSV-associated lower respiratory tract infection.
  • Severe outcomes were less prevalent in the nirsevimab group, including lower rates of PICU admission and need for ventilatory support.
  • The relative benefit of nirsevimab increased over time, with lower hospitalization risk observed after 30 days.
Interpretation:

Nirsevimab may provide better protection against RSV-related hospitalization and severe outcomes in infants compared to maternal vaccination, particularly beyond the first week after discharge.

Limitations:
  • Observational study design may include residual confounding despite matching.
  • Analysis reflects a single RSV season with limited follow-up.
  • Maternal vaccination was restricted to a specific gestational window, limiting generalizability.
Conclusion:

Both nirsevimab and maternal vaccination are effective in reducing RSV-related adverse outcomes, but nirsevimab shows lower hospitalization rates and severe outcomes in early infancy. Further studies are needed to evaluate their use.

Original Source(s)

Related Content